Cellular Biomedicine Group Inc (NASDAQ:CBMG) – B. Riley issued their Q1 2018 earnings per share estimates for shares of Cellular Biomedicine Group in a note issued to investors on Thursday. B. Riley analyst G. Zavoico anticipates that the biotechnology company will post earnings of ($0.47) per share for the quarter. B. Riley has a “Buy” rating and a $32.00 price target on the stock. B. Riley also issued estimates for Cellular Biomedicine Group’s Q2 2018 earnings at ($0.47) EPS, Q3 2018 earnings at ($0.49) EPS, Q4 2018 earnings at ($0.51) EPS, FY2018 earnings at ($1.94) EPS, FY2019 earnings at ($1.96) EPS, FY2020 earnings at ($1.92) EPS, FY2021 earnings at $1.22 EPS and FY2022 earnings at $10.43 EPS.
Several other research analysts have also issued reports on the stock. Maxim Group restated a “hold” rating on shares of Cellular Biomedicine Group in a report on Tuesday, March 6th. BidaskClub upgraded shares of Cellular Biomedicine Group from a “hold” rating to a “buy” rating in a report on Wednesday, January 10th.
Cellular Biomedicine Group (NASDAQ:CBMG) last released its quarterly earnings results on Tuesday, March 6th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.08). Cellular Biomedicine Group had a negative return on equity of 45.60% and a negative net margin of 7,564.10%. The firm had revenue of $0.07 million for the quarter.
In related news, insider Yihong Yao acquired 4,167 shares of the stock in a transaction dated Friday, December 22nd. The stock was bought at an average price of $12.00 per share, for a total transaction of $50,004.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Tony Liu acquired 29,167 shares of the stock in a transaction dated Friday, December 22nd. The stock was bought at an average price of $12.00 per share, with a total value of $350,004.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 41,667 shares of company stock valued at $500,004. Company insiders own 8.20% of the company’s stock.
An institutional investor recently bought a new position in Cellular Biomedicine Group stock. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Cellular Biomedicine Group Inc (NASDAQ:CBMG) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 10,041 shares of the biotechnology company’s stock, valued at approximately $107,000. Zurcher Kantonalbank Zurich Cantonalbank owned approximately 0.07% of Cellular Biomedicine Group as of its most recent SEC filing. Institutional investors and hedge funds own 2.79% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “B. Riley Weighs in on Cellular Biomedicine Group Inc’s Q1 2018 Earnings (CBMG)” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://sportsperspectives.com/2018/03/13/b-riley-weighs-in-on-cellular-biomedicine-group-incs-q1-2018-earnings-cbmg.html.
Cellular Biomedicine Group Company Profile
Cellular Biomedicine Group Inc is a United States-based company which is engaged in the development of cell therapy technologies. The Company develops proprietary cell therapies for the treatment of cancer and degenerative diseases. The Company conducts immuno-oncology and stem cell clinical trials in China using products from the good manufacturing practices (GMP) laboratory.
Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.